Version 1
: Received: 19 April 2020 / Approved: 20 April 2020 / Online: 20 April 2020 (15:53:56 CEST)
How to cite:
Mina, F.; Rahman, M.; Das, S.; Karmakar, S.; Billah, M. Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19. Preprints2020, 2020040367. https://doi.org/10.20944/preprints202004.0367.v1
Mina, F.; Rahman, M.; Das, S.; Karmakar, S.; Billah, M. Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19. Preprints 2020, 2020040367. https://doi.org/10.20944/preprints202004.0367.v1
Mina, F.; Rahman, M.; Das, S.; Karmakar, S.; Billah, M. Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19. Preprints2020, 2020040367. https://doi.org/10.20944/preprints202004.0367.v1
APA Style
Mina, F., Rahman, M., Das, S., Karmakar, S., & Billah, M. (2020). Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19. Preprints. https://doi.org/10.20944/preprints202004.0367.v1
Chicago/Turabian Style
Mina, F., Sumon Karmakar and Mutasim Billah. 2020 "Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19" Preprints. https://doi.org/10.20944/preprints202004.0367.v1
Abstract
The emergence of new type of viral pneumonia cases in China, on December 31, 2019; identified as the cause of human coronavirus, labeled as "COVID-19," took a heavy toll of death and reported cases of infected people all over the world, with the potential to spread widely and rapidly, achieved worldwide prominence but arose without the procurement guidance. There is an immediate need for active intervention and fast drug discovery against the 2019-nCoV outbreak. Herein, the study provides numerous candidates of drugs (either alone or integrated with another drugs) which could prove to be effective against 2019-nCoV, are under different stages of clinical trials. This review will offer rapid identification of a number of repurposable drugs and potential drug combinations targeting 2019-nCoV and preferentially allow the international research community to evaluate the findings, to validate the efficacy of the proposed drugs in prospective trials and to lead potential clinical practices.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
